AZA+IFX联合法治疗克罗恩病的效果及其对患者肠道通透性的影响  

Effects of AZA+IFX combined therapy on Crohn′s disease and its effect on intestinal permeability in patients

作　　者：卢翀 郑小娟[1] 胡益冰 李子美 LU Chong;ZHENG Xiaojuan;HU Yibing;LI Zimei(Department of Gastroenterology,Jinhua Central Hospital of Zhejiang Province,Jinhua321000,China)

机构地区：[1]浙江省金华市中心医院消化内科,浙江金华321000

出　　处：《中国现代医生》2021年第17期45-48,共4页China Modern Doctor

基　　金：浙江省医药卫生科技计划项目(2019RC302)。

摘　　要：目的探讨克罗恩病(CD)患者治疗过程中,不同治疗方案治疗的临床效果,结合具体的数据分析出最为适合的治疗方案。方法将2018年1月至2019年12月期间在金华市中心医院治疗的98例确诊CD患者分为两组,对照组50例,试验组48例。对照组采用硫唑嘌呤进行治疗,试验组采用英夫利昔单抗联合硫唑嘌呤共同进行治疗。比较两组患者的临床疗效、治疗前后血清炎症因子肿瘤坏死因子-α(TNF-α)、白细胞介素-12(IL-12)及白细胞介素-10(IL-10),和治疗前后清蛋白(ALB)、超敏C反应蛋白(CRP)及血沉(ESR)水平。结果两组患者的临床疗效比较,试验组患者的临床疗效为96.00%,高于对照组的81.25%,差异有统计学意义(P<0.05);治疗后试验组IL-10数值高于对照组,试验组IL-12及TNF-α数值低于对照组,差异均有统计学意义(P<0.05),两组治疗后与治疗前比较,差异均有统计学意义(P<0.05)。试验组患者治疗后ALB水平均增高,CRP及ESR水平均降低,差异有统计学意义(P<0.05)。两组治疗后与治疗前比较,差异均有统计学意义(P<0.05)。结论应用英夫利昔单抗联合硫唑嘌呤方案可有效改善克罗恩病患者的免疫功能和炎症细胞因子,治疗效果满意。Objective To explore the clinical effects of different treatment schemes in the treatment of Crohn′s disease(CD)patients,and to analyze the most suitable treatment scheme based on the specific data.Methods A total of 98 patients with diagnosed CD treated in Jinhua Central Hospital from January 2018 to December 2019 were divided into two groups,with 50 in the control group and 48 in the experimental group.The control group was treated with azathioprine,and the experimental group was treated with infliximab combined with azathioprine.Clinical efficacy,serum levels of inflammatory factors,tumor necrosis factor-α(TNF-α),interleukin-12(IL-12)and interleukin-10(IL-10),albumin(ALB),hypersensitive C-reactive protein(CRP)and erythrocytic sedimentation rates(ESR)before and after treatment were compared between the two groups.Results The clinical efficacy of the experimental group was 96.00%,which was higher than 81.25%of the control group,and the difference was statistically significant(P<0.05).After treatment,the value of IL-10 in the experimental group was higher than those in the control group,while the values of IL-12 and TNF-αin the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).Statistically significant differences were also observed in those values between the two groups after treatment and before treatment(P<0.05).After treatment,ALB levels in the experimental group were increased,while CRP and ESR levels were decreased,with statistically significant differences(P<0.05).Statistically significant differences were observed between the two groups after and before treatment(P<0.05).Conclusion The treatment of infliximab combined with azathioprine can effectively improve the immune function and inflammatory cytokines in patients with Crohn′s disease,and the therapeutic effect is satisfactory.

关 键 词：英夫利西单抗 克罗恩病 免疫功能 临床效果 

分 类 号：R574.1[医药卫生—消化系统]